^
    Back
    Association details:
    Biomarker:KRAS G12R
    Cancer:Thyroid Gland Anaplastic Carcinoma
    Drug:GSKJ4 (Jumonji H3K27 demethylase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Front Pharmacol
    Title:

    Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer

    Published date:
    05/13/2020
    Excerpt:
    The combination of GSK-J4 and doxorubicin significantly increased the inhibitory effect on proliferation, especially in KRAS-mutant ATC cells in vivo (inhibition rate 38.0%) and in vitro (suppresses rate Fa value 0.624, CI value 0.673). The invasion and migration abilities of the KRAS-mutant cell line were inhibited at a low concentration (p < 0.05).
    Secondary therapy:
    doxorubicin hydrochloride
    DOI:
    10.3389/fphar.2020.00632